Battle Royale: Systemic Versus Locoregional Therapy for Unresectable Hepatocellular Carcinoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29667887.
- Also identified by DOI 10.2214/AJR.17.19392.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This commentary discusses research examining comparisons of locoregional therapy with systemic therapy for unresectable hepatocellular carcinoma (HCC). Comparison of patient outcomes after locoregional or systemic therapy for HCC is confounded by selection bias, wherein patients chosen for locoregional therapy usually have better underlying liver function that may contribute to the observed longer survival.
Medical subject headings
- Carcinoma, Hepatocellular
- Chemoembolization, Therapeutic
- Liver Neoplasms